Botulinum toxin A: is it really that fragile a molecule?
- PMID: 21134042
- DOI: 10.1111/j.1524-4725.2010.01702.x
Botulinum toxin A: is it really that fragile a molecule?
Abstract
Background: Botulinum toxin A is considered to be an extremely fragile molecule, with recommended usage of some reconstituted botulinum toxin A formulations within 4 hours of reconstitution. Extreme caution is recommended to avoid agitation of the vial.
Objective: To determine whether the effect of reconstituted botulinum toxin A is maintained even when it is agitated vigorously.
Design: Experimental, comparative, animal study.
Participants: Sixty-four white Swiss Webster mice, aged 2 to 4 weeks, arranged in eight separate groups.
Intervention: Reconstituted onabotulinumtoxinA (2.5 U/0.1 mL) was placed securely in a battery-operated mechanized apparatus. The apparatus with the vial was placed in the refrigerator, and the apparatus continuously inverted and straightened the onabotulinumtoxinA vial 30 times a minute. Eight mice were each injected intraperitoneally with 1 U of the agitated onabotulinumtoxinA on days 1, 3, 5, 7, 14, 21, 28, and 42, to evaluate the efficacy of the continuously agitated onabotulinumtoxinA.
Main outcome measure: Death of the mice, demonstrating efficacy of the onabotulinumtoxinA molecule.
Results: Half of each group of mice (4/8 mice) died within 48 hours of the injection (range 16-48 hours).
Conclusion: The effect of botulinum toxin type A is maintained even when it is agitated vigorously for up to 6 weeks. The authors have indicated no significant interest with commercial supporters.
© 2010 by the American Society for Dermatologic Surgery, Inc.
Similar articles
-
Botulinum toxin type A: new information about an old medicine.Skin Therapy Lett. 2011 Sep;16(8):3-6. Skin Therapy Lett. 2011. PMID: 22089415
-
Differentiating toxins on new turf.Plast Surg Nurs. 2011 Jan-Mar;31(1):36-8. doi: 10.1097/PSN.0b013e3182090852. Plast Surg Nurs. 2011. PMID: 21368647 No abstract available.
-
The protein load of therapeutic botulinum toxins.Eur J Neurol. 2007 Apr;14(4):e11. doi: 10.1111/j.1468-1331.2007.01683.x. Eur J Neurol. 2007. PMID: 17388970 Review. No abstract available.
-
Dilution and storage of botulinum toxin.Dermatol Surg. 1998 Nov;24(11):1179-80. doi: 10.1111/j.1524-4725.1998.tb04094.x. Dermatol Surg. 1998. PMID: 9834735 Review.
-
Incorrect reconstitution of incobotulinumtoxinA leads to loss of neurotoxin.J Drugs Dermatol. 2014 Jun;13(6):735-8. J Drugs Dermatol. 2014. PMID: 24918566 Clinical Trial.
Cited by
-
A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus.J Rehabil Med. 2021 Jan 1;53(1):jrm00134. doi: 10.2340/16501977-2753. J Rehabil Med. 2021. PMID: 33057730 Free PMC article.
-
Current trends in needle-free jet injection: an update.Clin Cosmet Investig Dermatol. 2018 May 1;11:231-238. doi: 10.2147/CCID.S162724. eCollection 2018. Clin Cosmet Investig Dermatol. 2018. PMID: 29750049 Free PMC article. Review.
-
Do complexing proteins provide mechanical protection for botulinum neurotoxins?J Neural Transm (Vienna). 2019 Aug;126(8):1047-1050. doi: 10.1007/s00702-019-02023-x. Epub 2019 Jun 6. J Neural Transm (Vienna). 2019. PMID: 31168666
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical